ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / INGN
SMTI (55) AGPU (42) ZJYL (46) LAKE (26) ⌘ Pro Terminal →

Inogen Inc (INGN) — RQD Stock Rating Cockpit

$6.86 -5.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.78

Inogen Inc (INGN) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $182.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INGN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Inogen Inc (NASDAQ: INGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $6.86 (-5.51% 1D, market cap $182.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, INGN ranks #597 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INGN compare to SMTI and AGPU in the Health Care sector?
▼

Within the Health Care sector (Industrial Specialties), INGN carries a Roarable D- (35/100 RQD), trailing P/E of 8.5x, gross margin of 52.2%, and ROIC of -27.0%. By comparison, SMTI (Sanara MedTech Inc.) holds a D+ grade (55/100 RQD, P/E 8.1x, ROIC 16.3%, cap $301.6M) and AGPU (Axe Compute Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $92.7M). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INGN?
▼

Per INGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001294133), Inogen Inc generated $295.3M in revenue (+5.9% YoY), $22.7M in net income, and -$13.7M in free cash flow against $298.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.78 (-1.18%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510035
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Cash (3)Whales (13)SEC (7)Macro (7)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-10.3% Base Target
$9 Bull$6 Base$5 Bear
📬 FREE INGN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INGN)Realized 20D OHLCV Swing Band: ±8.1%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY INGN SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (37% of score)

20D Institutional Volume Accumulation (±8.1% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (20% of score)

Altman Z-Score 1.46 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
27
Grade E$6.34+5.5% Next Q
Q2 (-2Q)
30
Grade E$6.69+6.6% Next Q
Q3 (-1Q)
32
Grade E$7.13-3.8% Next Q
Current
35
Grade D-$6.86-8.5% Hist 90D α
Trajectory: E (27) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INGN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INGN currently carries a cautious 35/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.90) and Max Pain ($7.20) forces dealer call-delta covering toward $8.70.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
57.430 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
1.46>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE56% OF RANGE
L: $5$6.86H: $8
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 1 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 14 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on INGN

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (15)

-27.0% ROIC with 52.2% gross margin and -7.13% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (35)

Altman-Z 1.46 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (45)

20/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like INGN
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INGN)

  • ✓Walkthrough of INGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
INGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -1.58%📐 HORIZONTAL RANGE
2026-11-03O $7.26H $7.26L $6.86C $6.86VOL 201.2K
RES: $7.37SUP: $4.67SMA50: $5.90SMA200: $6.23
$7.60$6.91$6.22$5.53$4.84RES $7.37SUP $4.67$6.862026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INGN Butterfly Map → + Track INGN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-4.3%/yr Implied 5Y Growth

vs. +5.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on INGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INGN)

Health Care Rank #597 of 1015 ⚔️ SMTI vs INGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INGN vs. SMTI, AGPU, ZJYL, LAKE)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Inogen Inc (INGN) ranks #597 by composite RQD confidence (35/100, grade D-) and #587 by equity capitalization ($182.1M). Within this direct 5-issuer industry benchmark cohort, SMTI leads on earnings valuation at 8.1x trailing P/E, while SMTI leads on capital efficiency and profitability with 16.3% ROIC and 92.7% gross margin. SMTI currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with INGN at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
INGN ACTIVE
Inogen Inc
D- 35/100 8.5x 52.2% -27.0% -5.51% $182.1M Benchmark Subject
SMTI
Sanara MedTech Inc.
D+ 55/100 8.1x 92.7% 16.3% -0.26% $301.6M /smti-vs-ingn →
AGPU
Axe Compute Inc.
D- 42/100 — — -35.0% -8.78% $92.7M /agpu-vs-ingn →
ZJYL
JIN MEDICAL INTERNATIONAL LTD. (Class A)
D 46/100 — 29.2% — +26.34% $371.8M /zjyl-vs-ingn →
LAKE
Lakeland Industries Inc.
E 26/100 — 32.9% -9.5% -1.01% $87.3M /lake-vs-ingn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001294133 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Inogen Inc (INGN) reported GAAP revenue of $295.3M (+5.9% vs. FY2024 revenue of $278.8M , and +17.4% cumulative change since FY2023) , GAAP net income of $22.7M, operating cash flow of -$11.2M, and free cash flow of -$13.7M (-637.9% YoY). On the balance sheet, INGN closed FY2025 with $298.6M in total assets against $0 in total debt (Altman Z-Score: 1.46, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $295.3M $22.7M -$11.2M -$13.7M $298.6M —
FY2024 (FY) 2024-12-31 $278.8M $35.9M $5.9M $2.6M $296.2M —
FY2023 (FY) 2023-12-31 $251.6M $102.4M -$3.2M -$3.2M — —

3. INGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Inogen Inc (NASDAQ: INGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $6.86 (-5.51% 1D, market cap $182.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, INGN ranks #597 in composite RQD confidence.

How does INGN compare to SMTI and AGPU in the Health Care sector?

Within the Health Care sector (Industrial Specialties), INGN carries a Roarable D- (35/100 RQD), trailing P/E of 8.5x, gross margin of 52.2%, and ROIC of -27.0%. By comparison, SMTI (Sanara MedTech Inc.) holds a D+ grade (55/100 RQD, P/E 8.1x, ROIC 16.3%, cap $301.6M) and AGPU (Axe Compute Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $92.7M). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INGN?

Per INGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001294133), Inogen Inc generated $295.3M in revenue (+5.9% YoY), $22.7M in net income, and -$13.7M in free cash flow against $298.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INGN trading relative to its 50-day, 200-day, and 52-week technical levels?

INGN last traded at $6.86 (-5.51% on volume of 201,200 shares), positioning the stock +16.27% above its 50-day simple moving average ($5.90) and +10.11% above its 200-day simple moving average ($6.23). Across its 52-week range of $5.05 to $8.29, INGN sits at the 55.9% percentile with a 14-day RSI of 57.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.1% ($6.30 to $7.42).

Direct Sub-Reports: INGN RQD Cockpit INGN 12M Forecast INGN Earnings & Move INGN Dividends & DRIP INGN Insiders & 13F INGN Whale Options INGN Profit Sankey INGN News & Why
ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ SEC XBRL & RQD VERIFIED

INGN — Inogen Inc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Inogen Inc (INGN) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $6.86 (-5.51% 1D, market capitalization $182.1M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -27.0%, gross margin of 52.2%, operating margin of -10.2%, and free cash flow yield of -7.13%.
  • Whale 13F & Options Flow (13/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of 1.46, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Inogen Inc (INGN) is a NASDAQ-listed issuer classified under the Health Care sector and the Industrial Specialties industry. Per the financials, the company reported revenue of $295.3M for FY 2025, indicating an operating business of meaningful scale relative to its market capitalization.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Inogen Inc (INGN) reported $295.3M in annual revenue (up from $278.8M in FY2024, +5.9% YoY) and $22.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($251.6M revenue, $102.4M net income) through FY2025, INGN scaled operating cash flow to -$11.2M and free cash flow to -$13.7M, backed by $298.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -7.13% and institutional whale pillar of 13/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $5.05 – $8.29 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 8.5x trailing P/E against -10.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore contains no upstream or downstream dependency mapping, no sector correlation data, and no identified 2nd-order bottlenecks. A prospective investor should recognize that this section cannot confirm supply-chain exposure in either direction.

  • Key Question #1: Can INGN sustain or expand its -10.2% operating margin and -27.0% ROIC against Industrial Specialties peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $295.3M and free cash flow of -$13.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is INGN's 7.9x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

INGN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Inogen Inc (INGN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INGN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INGN Bull vs. Bear Conversation Board — What's Your Call at $6.86?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INGN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on INGN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $8.23 (+20.0%)
📌 Pinned Debate

Institutional accumulation (14/20 whale flow) and a low forward P/E of 7.9 suggest positioning and valuation support despite weak funda

Long INGN at $6.86 targeting $8.23. Institutional accumulation (14/20 whale flow) and a low forward P/E of 7.9 suggest positioning and valuation support despite weak fundamentals.. Institutional whale score is 13/20 and the risk/reward vs. the $5.05 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@FadeTheHype Shorting a 13/20 institutional whale-flow stock at $6.86 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $5.15 (-24.9%)
Spot @ $6.86

A -27% ROIC, -7.13% FCF yield, and a 1/20 cash engine score show the business is consuming capital, with a Simply Wall St RISK WATCH fl

Sitting on the sidelines or leaning short INGN above $6.86. A -27% ROIC, -7.13% FCF yield, and a 1/20 cash engine score show the business is consuming capital, with a Simply Wall St RISK WATCH flag on top.. Until Fundamental Cash Engine (1/20) and FCF yield (-7.13%) inflect higher, upside is capped near $8.29.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%